Answers are grounded in this paper and cite their sources.
Pancreatic cancer (PC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Baicalein, a major flavonoid derived from Scutellaria baicalensis Georgi, exhibits multiple antitumor activities, but its key targets and mechanisms in PC remain unclear. This study integrated network pharmacology, single-cell RNA sequencing (scRNA-seq), molecular docking, and in vitro experiments to investigate the potential mechanisms of baicalein against PC. Network pharmacology identified baicalein-related targets associated with PC, which were mainly enriched in receptor tyrosine kinase signaling, PI3K–AKT, MAPK, Ras, and apoptosis-related pathways. Single-cell transcriptomic analysis revealed heterogeneous SRC expression across epithelial subpopulations, with higher expression observed in Cluster 1, and dynamic changes during epithelial cell state transitions. Molecular docking predicted favorable interactions between baicalein and key proteins, including SRC and EGFR. In vitro experiments further showed that baicalein significantly reduced PC cell viability and decreased SRC protein expression. These findings suggest that baicalein may exert antitumor effects in PC through multiple targets and pathways, with SRC representing a potential key target, providing a theoretical basis for further evaluation of baicalein as an adjuvant therapeutic candidate for PC.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: